Liver-directed gene therapy of diabetic rats using an HVJ-E vector containing EBV plasmids expressing insulin and GLUT 2 transporter

Gene Therapy

Volumn 13, Issue 3, 2006, Pages 216-224

  Kim, Y D ^a   Park, K G ^a   Morishita, R ^b   Kaneda, Y ^b   Kim, S Y ^a   Song, D K ^a   Kim, H S ^a   Nam, C W ^a   Lee, H C ^c   Lee, K U ^d   Park, J Y ^d   Kim, B W ^e   Kim, J G ^e   Lee, I K ^e  

^a Keimyung University School of Medicine   (South Korea)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c Yonsei University College of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Kyungpook National University School of Medicine   (South Korea)

Author keywords

Diabetes; EBV; GLUT 2; HVJ E; Insulin

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; GLUCOSE TRANSPORTER 2; INSULIN; POTASSIUM CHANNEL; STREPTOZOCIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; MALE; NONHUMAN; PARAINFLUENZA VIRUS; PLASMID; POSTPRANDIAL STATE; PRIORITY JOURNAL; RAT; REPLICON; STREPTOZOCIN DIABETES; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GLUCOSE TRANSPORTER TYPE 2; HERPESVIRUS 4, HUMAN; INSULIN; LIVER; MALE; POTASSIUM CHANNELS; RATS; RATS, SPRAGUE-DAWLEY; SENDAI VIRUS; TIME FACTORS; TRANSDUCTION, GENETIC; VIRAL ENVELOPE PROTEINS;

ANIMALIA; HUMAN HERPESVIRUS 4;

EID: 31444444251     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302644     Document Type: Article

References (36)

1. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-460.
2. Thompson L. At age 2, gene therapy enters a growth phase. Science 1992; 258: 744-746.
3. Hollingsworth SJ, Barker SG. Gene therapy: Into the future of surgery. Lancet 1999; 353 (Suppl): SI19-SI20.
4. Yoon JW, Jun HS. Recent advances in insulin gene therapy for type 1 diabetes. Trends Mol Med 2002; 8: 62-68.
5. Yechoor V, Chan L. Gene therapy progress and prospects: Gene therapy for diabetes mellitus. Gene Therapy 2004; 12: 101-107.
6. Lee HC, Kim SJ, Kim KS, Shin HC, Yoon JW. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature 2000; 408: 483-488.
7. Chen R, Meseck ML, Woo SL. Auto-regulated hepatic insulin gene expression in type 1 diabetic rats. Mol Ther 2001; 3: 584-590.
8. Mitanchez D, Chen R, Massias JF, Porteu A, Mignon A, Bertagna X et al. Regulated expression of mature human insulin in the liver of transgenic mice. FEBS Lett 1998; 421: 285-289.
9. Liu GJ, Simpson AM, Swan MA, Tao C, Tuch BE, Crawford RM et al. ATP-sensitive potassium channels induced in liver cells after transfection with insulin cDNA and the GLUT 2 transporter regulate glucose-stimulated insulin secretion. FASEB J 2003; 17: 1682-1684.
10. Min KA, Oh ST, Yoon KH, Kim CK, Lee SK. Prolonged gene expression in primary porcine pancreatic cells using an Epstein-Barr virus-based episomal vector. Biochem Biophys Res Commun 2003; 305: 108-115.
11. Saeki Y, Wataya-Kaneda M, Tanaka K, Kaneda Y. Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ liposomes. Gene Therapy 1998; 5: 1031-1037.
12. Tsujie M, Isaka Y, Nakamura H, Kaneda Y, Imai E, Hori M. Prolonged transgene expression in glomeruli using an EBV replicon vector system combined with HVJ liposomes. Kidney Int 2001; 59: 1390-1396.
13. Lupton S, Levine AJ. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells. Mol Cell Biol 1985; 5: 2533-2542.
14. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
15. Wu H, Kapoor P, Frappier L. Separation of the DNA replication, segregation, transcriptional activation functions of Epstein-Barr nuclear antigen 1. J Virol 2002; 76: 2480-2490.
16. Ilan Y, Saito H, Thummala NR, Chowdhury NR. Adenovirus-mediated gene therapy of liver diseases. Semin Liver Dis 1999; 19: 49-59.
17. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-976.
18. Park YM, Woo S, Lee GT, Ko JY, Lee Y, Zhao ZS et al. Safety and efficacy of adeno-associated viral vector-mediated insulin gene transfer via portal vein to the livers of streptozotocin-induced diabetic Sprague-Dawley rats. J Gene Med 2005; 7: 621-629.
19. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
20. Russell DW, Kay MA. Adeno-associated virus vectors and haematology. Blood 1999; 94: 864-874.
21. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-932.
22. Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996; 93: 11421-11425.
23. Ahn JD, Morishita R, Kaneda Y, Kim HS, Chang YC, Lee KU et al. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia. Gene Therapy 2002; 9: 1682-1692.
24. Ahn JD, Morishita R, Kaneda Y, Kim HJ, Kim YD, Lee HJ et al. Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Therapy 2004; 11: 916-923.
25. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Systemic administration of HVJ viral coat-liposome complex containing human insulin vector decreases glucose level in diabetic mouse: A model of gene therapy. Biochem Biophys Res Commun 2000; 273: 666-674.
26. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6: 219-226.
27. Burcelin R, Dolci W, Thorens B. Glucose sensing by the hepatoportal sensor is GLUT2-dependent: In vivo analysis in GLUT2-null mice. Diabetes 2000; 49: 1643-1648.
28. ATP channels regulate mitogenically induced proliferation in primary rat hepatocytes and human liver cell lines. Implications for liver growth control and potential therapeutic targeting. J Biol Chem 2000; 275: 26050-26057.
29. Henderson RM, Graf J, Boyer JL. Inward-rectifying potassium channels in rat hepatocytes. Am J Physiol 1989; 171: G1028-G1035.
30. Nishikawa M, Huang L. Nonviral vectors in the new millennium: Delivery barriers in gene transfer. Hum Gene Ther 2001; 12: 861-870.
31. Kaneda Y, Iwai K, Uchida T. Introduction and expression of the human insulin gene in adult rat liver. J Biol Chem 1989; 264: 12126-12129.
32. Calos MP. The potential of extrachromosomal replicating vectors for gene therapy. Trends Genet 1996; 12: 463-466.
33. Yasutomi K, Itokawa Y, Asada H, Kishida T, Cui FD, Ohashi S et al. Intravascular insulin gene delivery as potential therapeutic intervention in diabetes mellitus. Biochem Biophys Res Commun 2003; 310: 897-903.
34. Chen ZY, Yant SR, He CY, Meuse L, Shen S. Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver. Mol Ther 2001; 3: 403-410.
35. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003; 8: 495-500.
36. Fregien N, Davidson N. Activating elements in the promoter region of the chicken beta-actin gene. Gene 1986; 48: 1-11.